The effect of P2Y12 inhibitors on non-critically ill COVID-19 patients did not increase odds of improvement and reduced hospitalization (149), whereas treatment with IL-6 receptor antagonists tocilizumab and sarilumab did improve survival outcomes among critically ill COVID-19 patients (150). This evidence concerns the gene P2RY12 and COVID-19.